1. Tapper, E.B. & Parikh, N.D. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ 362, k2817 (2018).
2. Wilde, B. & Katsounas, A. Immune Dysfunction and Albumin-Related Immunity in Liver Cirrhosis. Mediators Inflamm 2019, 7537649 (2019).
3. Kwong, A., et al. OPTN/SRTR 2018 Annual Data Report: Liver. Am J Transplant 20 Suppl s1, 193-299 (2020).
4. Code of Federal Regulation (CFR) annual edition. in Title 42: Public Health, Vol. Part 121 - Organ Procurement and Transplantationation Network (ed. Services, D.o.H.a.H.).
5. Wiesner, R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124, 91-96 (2003).
6. Elwir, S. & Lake, J. Current Status of Liver Allocation in the United States. Gastroenterol Hepatol (N Y) 12, 166-170 (2016).
7. Polyak, A., Kuo, A. & Sundaram, V. Evolution of liver transplant organ allocation policy: Current limitations and future directions. World J Hepatol 13, 830-839 (2021).
8. Freeman, R.B., Jr., et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 8, 851-858 (2002).
9. Kamath, P.S., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33, 464-470 (2001).
10. Trotter, J.F. & Osgood, M.J. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA 291, 1871-1874 (2004).
11. Biggins, S.W., et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130, 1652-1660 (2006).
12. Allen, A.M., et al. Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. Transplantation 102, 1710-1716 (2018).
13. Asrani, S.K., et al. MELD-GRAIL-Na: Glomerular Filtration Rate and Mortality on Liver-Transplant Waiting List. Hepatology 71, 1766-1774 (2020).
14. Kim, W.R., et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology 161, 1887-1895 e1884 (2021).
15. Sundaram, V., et al. Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14-Day Waitlist Mortality Than Status-1a Patients. Hepatology 70, 334-345 (2019).
16. Engelmann, C., Zhang, I.W. & Claria, J. Mechanisms of immunity in acutely decompensated cirrhosis and acute-on-chronic liver failure. Liver Int (2023).
17. Bayona Molano, M.D.P., Barrera Gutierrez, J.C., Landinez, G., Mejia, A. & Haskal, Z.J. Updates on the Model for End-Stage Liver Disease Score and Impact on the Liver Transplant Waiting List: A Narrative Review. J Vasc Interv Radiol 34, 337-343 (2023).
18. Schlegel, A., et al. Risk Assessment in High- and Low-MELD Liver Transplantation. Am J Transplant 17, 1050-1063 (2017).
19. Lai, J.C., et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 66, 564-574 (2017).
20. Jacob, M., et al. Pretransplant MELD score and post liver transplantation survival in the UK and Ireland. Liver Transpl 10, 903-907 (2004).
21. Desai, N.M., et al. Predicting outcome after liver transplantation: utility of the model for end-stage liver disease and a newly derived discrimination function. Transplantation 77, 99-106 (2004).
22. Rana, A., et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 8, 2537-2546 (2008).
23. Dutkowski, P., et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg 254, 745-753; discussion 753 (2011).
24. Petrowsky, H., et al. Liver transplantation in highest acuity recipients: identifying factors to avoid futility. Ann Surg 259, 1186-1194 (2014).
25. Halldorson, J.B., Bakthavatsalam, R., Fix, O., Reyes, J.D. & Perkins, J.D. D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. Am J Transplant 9, 318-326 (2009).
26. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40, 373-383 (1987).
27. Cholongitas, E. & Burroughs, A.K. The evolution in the prioritization for liver transplantation. Ann Gastroenterol 25, 6-13 (2012).
28. Gimson, A. Development of a UK liver transplantation selection and allocation scheme. Curr Opin Organ Transplant 25, 126-131 (2020).
29. Lee, E.G., Perini, M.V., Makalic, E., Oniscu, G.C. & Fink, M.A. External Validation of the United Kingdom Transplant Benefit Score in Australia and New Zealand. Prog Transplant 33, 25-33 (2023).
30. Ravaioli, M., et al. Risk Avoidance and Liver Transplantation: A Single-center Experience in a National Network. Ann Surg 264, 778-786 (2016).
31. Montano-Loza, A.J. Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol 20, 8061-8071 (2014).
32. Purnak, T. & Yilmaz, Y. Liver disease and malnutrition. Best Practice & Research Clinical Gastroenterology 27, 619-629 (2013).
33. Lai, J.C., Volk, M.L., Strasburg, D. & Alexander, N. Performance-Based Measures Associate With Frailty in Patients With End-Stage Liver Disease. Transplantation 100, 2656-2660 (2016).
34. Nafea, M.A., et al. Predictors of early recipient mortality after living donor liver transplantation in a tertiary care center in Egypt. Ann Saudi Med 39, 337-344 (2019).
35. Chong, J., et al. Perioperative Skeletal Muscle Fluctuations in High-Acuity Liver Transplantation. J Surg Res 270, 386-393 (2022).
36. Ayorinde, T., Panayotova, G., Sharma, A. & Lunsford, K.E. Clinical and biomarker assessment of frailty in liver transplantation. Curr Opin Organ Transplant 26, 488-497 (2021).
37. McGovern, B.H., et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 44, 431-437 (2007).
38. Schirren, C.A., et al. Analysis of T cell activation pathways in patients with liver cirrhosis, impaired delayed hypersensitivity and other T cell-dependent functions. Clin Exp Immunol 108, 144-150 (1997).
39. Spinozzi, F., et al. T-lymphocyte activation pathways in alcoholic liver disease. Immunology 73, 140-146 (1991).
40. Laso, F.J., et al. Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake. Alcohol Clin Exp Res 21, 1226-1231 (1997).
41. Laso, F.J., et al. Chronic alcoholism is associated with an imbalanced production of Th-1/Th-2 cytokines by peripheral blood T cells. Alcohol Clin Exp Res 23, 1306-1311 (1999).
42. Jothimani, D., Venugopal, R., Vij, M. & Rela, M. Post liver transplant recurrent and de novo viral infections. Best Pract Res Clin Gastroenterol 46-47, 101689 (2020).
43. Friedrich, K., et al. Multidrug-Resistant Bacteria and Disease Progression in Patients with End-Stage Liver Disease and after Liver Transplantation. J Gastrointestin Liver Dis 28, 303-310 (2019).
44. Albillos, A., et al. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol 19, 112-134 (2022).
45. van Vugt, J.L.A., et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort. J Hepatol 68, 707-714 (2018).
46. Thuluvath, P.J., Thuluvath, A.J., Savva, Y. & Zhang, T. Karnofsky Performance Status Following Liver Transplantation in Patients With Multiple Organ Failures and Probable Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol 18, 234-241 (2020).
47. Irvine, K.M., Ratnasekera, I., Powell, E.E. & Hume, D.A. Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Front Immunol 10, 293 (2019).
48. Liaskou, E. & Hirschfield, G.M. Cirrhosis-associated immune dysfunction: Novel insights in impaired adaptive immunity. EBioMedicine 50, 3-4 (2019).
49. Lawitz, E., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368, 1878-1887 (2013).
50. Mathur, K., et al. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. Clin Transl Gastroenterol 12, e00420 (2021).
51. Young, K., Liu, B., Bhuket, T., Gish, R.G. & Wong, R.J. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. J Viral Hepat 26, 350-361 (2019).
52. Arias, A.B.V., et al. Indication for Liver Transplantation After Direct-Acting Agents in the Treatment of Patients With Hepatitis C. Transplant Proc 54, 32-34 (2022).
53. Deutsch-Link, S., et al. Alcohol-Associated Liver Disease Mortality Increased From 2017 to 2020 and Accelerated During the COVID-19 Pandemic. Clin Gastroenterol Hepatol 20, 2142-2144 e2142 (2022).
54. Shaikh, A., et al. Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. Transplant Direct 8, e1313 (2022).
55. McCabe, P., Gish, R.G., Cheung, R. & Wong, R.J. More Severe Deficits in Performance Status at Time of Liver Transplant is Associated With Significantly Higher Risk of Death Following Liver Transplantation. J Clin Gastroenterol 53, e392-e399 (2019).
56. Feng, S., et al. Characteristics associated with liver graft failure: the concept of a donor risk index. American Journal of Transplantation 6, 783-790 (2006).
57. Markwick, L.J., et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology 148, 590-602 e510 (2015).
58. Lebosse, F., et al. CD8(+)T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. EBioMedicine 49, 258-268 (2019).
59. Mysore, K.R., et al. Longitudinal assessment of T cell inhibitory receptors in liver transplant recipients and their association with posttransplant infections. Am J Transplant 18, 351-363 (2018).
60. O'Keefe, S.J., El-Zayadi, A.R., Carraher, T.E., Davis, M. & Williams, R. Malnutrition and immuno-incompetence in patients with liver disease. Lancet 2, 615-617 (1980).
61. Kritikos, A. & Manuel, O. Bloodstream infections after solid-organ transplantation. Virulence 7, 329-340 (2016).
62. Bambha, K., et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant 4, 1798-1804 (2004).
63. Kalathil, S., Lugade, A.A., Miller, A., Iyer, R. & Thanavala, Y. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res 73, 2435-2444 (2013).
64. Rivas-Fuentes, S., Salgado-Aguayo, A., Arratia-Quijada, J. & Gorocica-Rosete, P. Regulation and biological functions of the CX3CL1-CX3CR1 axis and its relevance in solid cancer: A mini-review. J Cancer 12, 571-583 (2021).
65. White, G.E. & Greaves, D.R. Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators.
66. Pachot, A., et al. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression. J Immunol 180, 6421-6429 (2008).
67. Hoogendijk, A.J., et al. Plasma fractalkine is a sustained marker of disease severity and outcome in sepsis patients. Crit Care 19, 412 (2015).
68. Chen, X., Wei, Q., Hu, Y. & Wang, C. Role of Fractalkine in promoting inflammation in sepsis-induced multiple organ dysfunction. Infect Genet Evol 85, 104569 (2020).
69. Nerusu, K.C., et al. Matrix metalloproteinase-3 (stromelysin-1) in acute inflammatory tissue injury. Exp Mol Pathol 83, 169-176 (2007).
70. Parks, W.C., Wilson, C.L. & Lopez-Boado, Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4, 617-629 (2004).
71. Zuo, X., Pan, W., Feng, T., Shi, X. & Dai, J. Matrix metalloproteinase 3 promotes cellular anti-dengue virus response via interaction with transcription factor NFkappaB in cell nucleus. PLoS One 9, e84748 (2014).
72. Si-Tayeb, K., et al. Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol 169, 1390-1401 (2006).
73. Cursio, R., et al. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor.
74. Handley, S.A. & Miller, V.L. General and specific host responses to bacterial infection in Peyer's patches: a role for stromelysin-1 (matrix metalloproteinase-3) during Salmonella enterica infection. Mol Microbiol 64, 94-110 (2007).
75. Li, C.K., et al. Impaired immunity to intestinal bacterial infection in stromelysin-1 (matrix metalloproteinase-3)-deficient mice. J Immunol 173, 5171-5179 (2004).
76. Martin, G., et al. Role of plasma matrix-metalloproteases (MMPs) and their polymorphisms (SNPs) in sepsis development and outcome in ICU patients. Sci Rep 4, 5002 (2014).
77. Fiotti, N., et al. Genetic Variants of Matrix Metalloproteinase and Sepsis: The Need Speed Study. Biomolecules 12(2022).
78. Ricarte-Bratti, J.P., Brizuela, N.Y., Jaime-Albarran, N. & Montrull, H.L. IL-6, MMP 3 and prognosis in previously healthy sepsis patients. Rev Fac Cien Med Univ Nac Cordoba 74, 99-106 (2017).
79. Jones, T.K., et al. Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis. Shock 57, 41-47 (2022).
80. Bowen, D.G. & Walker, C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436, 946-952 (2005).
81. Wedemeyer, H., Khera, T., Strunz, B. & Björkström, N.K. Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset? Front Immunol 11, 571166 (2020).
82. Li, H., Li, T., Crispe, I.N. & Tu, Z. HCV immune evasion and regulatory T cell activation: cause or consequence? Cellular & Molecular Immunology 15, 536-538 (2018).
83. Abbas, A.K., et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 14, 307-308 (2013).
84. Manigold, T., et al. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 107, 4424-4432 (2006).
85. Arora, S.S., et al. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study. Transpl Int 32, 854-864 (2019).
86. Panayotova, G.G., et al. Identification and Internal Validation of a Novel Pre-Transplant Biomarker Panel to Predict Mortality Following Liver Transplantation: The Liver Immune Frailty Index. Preprint (Version 2) available at Research Square (2022).
87. Kwong, A.J., et al. OPTN/SRTR 2021 Annual Data Report: Liver. Am J Transplant 23, S178-S263 (2023).
88. Pepe, M.S., Feng, Z., Janes, H., Bossuyt, P.M. & Potter, J.D. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100, 1432-1438 (2008).
89. Ou, F.S., Michiels, S., Shyr, Y., Adjei, A.A. & Oberg, A.L. Biomarker Discovery and Validation: Statistical Considerations. J Thorac Oncol 16, 537-545 (2021).
90. Lunsford, K.E., et al. Delayed Implantation of Pumped Kidneys Decreases Renal Allograft Futility in Combined Liver-Kidney Transplantation. Transplantation 104, 1591-1603 (2020).
91. McCabe, P. & Wong, R.J. More severe deficits in functional status associated with higher mortality among adults awaiting liver transplantation. Clin Transplant 32, e13346 (2018).
92. Disease, N.I.o.A.a.I. Standard Operating Procedure: Peripheral Blood Mononuclear Cells (PBMC) and Associated Plasma Collection. Vol. 2022 (2021).
93. Riley, R.D., et al. Calculating the sample size required for developing a clinical prediction model. BMJ 368, m441 (2020).
94. Hastie, T., Tibshirani, R. & Wainwright, M. Statistical Learning with Sparsity: The Lasso and Generalizations, (CRC Press, Boca Raton, FL, 2015).
95. StataCorp. Stata Lasso Reference Manual, (Stata Press, College Station, TX, 2019).